Bullish drug business probable in the second half of this year

Published: 2002-06-18 07:00:00

Updated: 2002-06-18 07:00:00

Korea's drug business is likely to be bullish in the second of this year, according to various reports released by some securities and bank analysts, while they worried the domestic cut-throat competition may results in inducing a higher proportion of sales administrative expenses.

Market anal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK